Blar i forfatter "Gribbestad, Ingrid S"

Viser treff 1-3 av 3

    • Interplay of choline metabolites and genes in patient-derived breast cancer xenografts 

      Grinde, Maria Tunset; Skrbo, Nirma; Moestue, Siver Andreas; Rødland, Einar Andreas; Borgan, Eldrid; Kristian, Alexandr; Sitter, Beathe; Bathen, Tone; Børresen-Dale, Anne-Lise; Mælandsmo, Gunhild; Sørlie, Therese; Marangoni, Elisabetta; Gribbestad, Ingrid S (Journal article; Tidsskriftartikkel; Peer reviewed, 2014-01-21)
      Introduction: Dysregulated choline metabolism is a well-known feature of breast cancer, but the underlying mechanisms are not fully understood. In this study, the metabolomic and transcriptomic characteristics of a large panel of human breast cancer xenograft models were mapped, with focus on choline metabolism. <br> Methods: Tumor specimens from 34 patient-derived xenograft models were collected ...

    • Metabolic biomarkers for response to PI3K inhibition in basal-like breast cancer 

      Moestue, Siver Andreas; Dam, Cornelia Gerarda; Gorad, Saurabh Sayajirao; Kristian, Alexandr; Bofin, Anna M.; Mælandsmo, Gunhild; Engebråten, Olav; Gribbestad, Ingrid S; Bjørkøy, Geir (Journal article; Tidsskriftartikkel; Peer reviewed, 2013)
      Introduction: The phosphatidylinositol 3-kinase (PI3K) pathway is frequently activated in cancer cells through numerous mutations and epigenetic changes. The recent development of inhibitors targeting different components of the PI3K pathway may represent a valuable treatment alternative. However, predicting efficacy of these drugs is challenging, and methods for therapy monitoring are needed. ...

    • Subtype-specific response to bevacizumab is reflected in the metabolome and transcriptome of breast cancer xenografts 

      Borgan, Eldrid; Lindholm, Evita Maria; Moestue, Siver Andreas; Mælandsmo, Gunhild; Lingjærde, Ole Christian; Gribbestad, Ingrid S; Børresen-Dale, Anne-Lise; Engebråten, Olav; Sørlie, Therese (Journal article; Tidsskriftartikkel; Peer reviewed, 2012-10-23)
      <p>Antiangiogenic therapy with bevacizumab has shown varying results in breast cancer clinical trials. Identifying robust biomarkers for selecting patients who may benefit from such treatment and for monitoring response is important for the future use of bevacizumab.</p> <p>Two established xenograft models representing basal‐like and luminal‐like breast cancer were used to study bevacizumab ...